Cytokinetics CYTK Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$206.03M-27.7% | -$183.03M-22.0% | -$306.18M-90.7% | -$134.37M+6.2% | -$161.38M-19.0% | ||
| $3.38M+46.9% | $2.86M+20.1% | $2.68M+11.1% | $2.29M-5.0% | $2.3M-1.3% | ||
| $30.39M+29.1% | $30.51M+16.2% | $30.7M+21.1% | $27.54M+11.8% | $23.55M+9.0% | ||
| -$10.94M+25.3% | $15.96M-2.7% | -$6.6M-2,806% | $6.4M+867% | -$14.64M-3,160% | ||
| $3.57M— | —— | —— | —— | $0— | ||
| $1.52M+133% | —— | $6.6M— | —— | -$4.58M+55.5% | ||
| -$6.21M+56.8% | $26.37M+162% | $7.62M+38.2% | $13.99M+235% | -$14.37M-158% | ||
| -$2.06M-647% | $4.2M-50.3% | -$6.28M-40.3% | $4.64M+157% | $376K-94.3% | ||
| -$3.95M-344% | -$3.53M— | -$2.68M— | -$1.66M— | $1.62M+184% | ||
| $41K— | —— | —— | -$51.03M— | $0— | ||
| -$145.46M-10.5% | -$142.65M-118% | -$107.51M-5.9% | -$128.24M-29.1% | -$131.62M-1.6% | ||
| $5.93M+4.7% | $5.64M+338% | $9.35M+1,234% | $4.15M+116% | $5.66M— | ||
| $106.52M-33.1% | $345.65M+185% | $335.45M+56.5% | $222.97M-72.7% | $159.11M+11.5% | ||
| $257.94M-6.5% | $8K— | $1K— | —— | $275.73M+57.3% | ||
| $145.49M+37.3% | —— | —— | $52.88M+108% | $105.96M+225% | ||
| —— | $182.37M— | $182.37M— | $182.37M— | $182.37M— | ||
| $2.74M+2.0% | $2.72M+1.9% | $2.71M+1.9% | $2.7M+1.9% | $2.68M+280% | ||
| $11.35M— | $14.65M+126% | $6.94M+9.7% | $14.4M— | $0-100% | ||
| $0-100% | —— | —— | $2K-99.1% | $202K-11.0% | ||
| $841K+6,369% | $1.22M+3.3% | $720K— | $514K— | $13K-99.9% | ||
| $7.77M+63.4% | $110.71M+4,544% | $330.47M+9,549% | $78.53M-90.4% | $4.75M-95.4% | ||
| -$483K-78.9% | —— | —— | -$682K-4,363% | -$270K-1,100% | ||
| $7.32M+135% | —— | $152.03M+206% | —— | -$21.18M-405% | ||
| $1.59M-83.6% | $3.04M+378% | $9.62M-33.4% | $606K-9.8% | $9.65M-5.5% | ||
| $1.5M+475% | $900K-25.0% | $700K0.0% | $3M+600% | -$400K— | ||
| —— | $0+100% | $0+100% | $0+100% | $0+100% | ||
| $1.52M+133% | —— | $6.6M— | —— | -$4.58M+55.5% | ||
| $41K— | —— | —— | -$51.03M— | $0— | ||
| -$1.04M+51.5% | -$4.22M-109% | -$2.15M-18.5% | -$2.32M-37.3% | -$2.14M-25.2% | ||
| -$3.95M-344% | -$3.53M— | -$2.68M— | -$1.66M— | $1.62M+184% | ||
| -$2.06M-647% | $4.2M-50.3% | -$6.28M-40.3% | $4.64M+157% | $376K-94.3% | ||
| -$1.87M+69.6% | -$3.08M+60.1% | -$2.7M+75.7% | -$4.03M+52.6% | -$6.17M-18.2% | ||
| -$1.6M-141% | —— | -$2.8M+81.6% | -$14.6M-7,400% | $3.9M— | ||
| $18.82M+33.4% | $16.06M+17.4% | $15M+11.9% | $13.21M+13.9% | $14.1M+37.7% | ||
| $1.59M+28.9% | $1.61M+38.6% | $1.47M+33.5% | $1.34M+26.8% | $1.23M+23.6% | ||
| $8.46M+145% | $8.47M+140% | $5.65M+62.0% | $5.33M+100% | $3.45M+83.8% | ||
| $61K— | $8K-57.9% | $1K— | $16K— | $0— | ||
| $257.94M-6.5% | $280.09M+20.1% | $273.83M+61.0% | $274M+65.5% | $275.73M+57.3% | ||
| $0-100% | —— | —— | $2K-99.1% | $202K-11.0% | ||
| —— | $43.75M-12.5% | $43.75M-12.5% | $43.75M-12.5% | $43.75M-12.5% | ||
| —— | $0-100% | $0-100% | —— | —— | ||
| $11.35M+48.3% | $14.65M+126% | $6.94M+9.7% | $6.75M-36.9% | $7.65M-74.1% | ||
| $4.19M+180% | $562K-80.5% | —— | $1.34M— | $1.49M-14.8% | ||
| $170K-95.1% | —— | $2.93M+1,378% | —— | $3.5M+1,867% | ||
| -$151.39M-10.3% | -$148.3M-122% | -$116.86M-14.3% | -$132.38M-30.8% | -$137.28M-6.0% | ||
| -$151.39M-10.3% | -$148.3M-122% | -$116.86M-14.3% | -$132.38M-30.8% | -$137.28M-6.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Cytokinetics generate?
- Cytokinetics (CYTK) generated -$523.8M in operating cash flow over the trailing twelve months.
- What is Cytokinetics's free cash flow?
- After $25.1M of capital expenditures, Cytokinetics's free cash flow was -$548.9M over the trailing twelve months, down 34.7% year over year.
- Where does Cytokinetics's cash flow data come from?
- Every line is extracted from Cytokinetics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
